IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

This trial is testing a new drug called IACS-6274, alone and in combination with other chemotherapy agents, in patients with advanced solid tumors that have progressed despite standard treatments. It focuses on cancers with specific genetic mutations or low levels of a particular enzyme. **You may be eligible if...** - You are 18 or older with advanced solid tumors that have grown despite prior treatment - Your cancer has specific genetic mutations (such as KEAP1, NFE2L2, STK11, NF1, PIK3CA, AKT, or PTEN changes) or specific tumor characteristics - For some parts of the study, you may have platinum-resistant ovarian cancer - You have been on at least one prior line of therapy - Your organ function and blood counts are adequate **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have severe heart, liver, or kidney problems - You have uncontrolled infections or active autoimmune diseases - You have received recent cancer treatment without adequate washout period - You have brain metastases that are symptomatic or untreated Talk to your doctor to see if this trial is right for you.